Trilaciclib
- TRADE NAME: Cosela (G1 Therapeutics)
- INDICATIONS: Reduction of the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor, Kinase inhibitor
- HALF-LIFE: ~14 hours
FDA APPROVAL DATE: 02/12/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Cisplatin, Dalfampridine, Dofetilide, Metformin
Trilaciclib can cause fetal harm when administered to pregnant women. Advise female patients of reproductive potential to use effective contraception during treatment with trilaciclib and for at least 3 weeks after the final dose.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric